keyword
MENU ▼
Read by QxMD icon Read
search

Premenopausal Breast Cancer

keyword
https://www.readbyqxmd.com/read/30314755/evaluation-of-progressive-hepatic-histopathology-in-long-term-tamoxifen-therapy
#1
Sandra Leal, Lídia Rocha, Ana Silva, Juliana Faria, Ricardo Jorge Dinis-Oliveira, Susana I Sá
Tamoxifen (TAM) therapy is the better treatment for breast cancer and the drug use the prophylaxis of this disease in young premenopausal women. Yet, the effects associated with this therapy are unknown. To better understand the extension of this problem, we developed an animal model to mimic this therapy, aiming to evaluate its potential biochemical and histopathological changes in the liver. Young cycling female rats were treated with TAM for one, two and three months and toxicological biomarkers and liver histomorphometry were evaluated...
October 3, 2018: Pathology, Research and Practice
https://www.readbyqxmd.com/read/30314564/personal-reproductive-and-familial-characteristics-associated-with-bilateral-oophorectomy-in-premenopausal-women-a-population-based-case-control-study
#2
Walter A Rocca, Liliana Gazzuola Rocca, Carin Y Smith, Brandon R Grossardt, Stephanie S Faubion, Lynne T Shuster, Elizabeth A Stewart, Michelle M Mielke, Kejal Kantarci, Virginia M Miller
OBJECTIVES: We investigated the association of personal, reproductive, and familial characteristics with bilateral oophorectomy performed for nonmalignant indications in a US population. STUDY DESIGN: In an established cohort study, we used the records-linkage system of the Rochester Epidemiology Project (REP http://www.rochesterproject.org) to identify 1653 premenopausal women who underwent bilateral oophorectomy in Olmsted County, Minnesota between 1988 and 2007 for a nonmalignant indication...
November 2018: Maturitas
https://www.readbyqxmd.com/read/30312457/height-and-body-mass-index-as-modifiers-of-breast-cancer-risk-in-brca1-2-mutation-carriers-a-mendelian-randomization-study
#3
Frank Qian, Shengfeng Wang, Jonathan Mitchell, Lesley McGuffog, Daniel Barrowdale, Goska Leslie, Jan C Oosterwijk, Wendy K Chung, D Gareth Evans, Christoph Engel, Karin Kast, Cora M Aalfs, Muriel A Adank, Julian Adlard, Bjarni A Agnarsson, Kristiina Aittomäki, Elisa Alducci, Irene L Andrulis, Banu K Arun, Margreet G E M Ausems, Jacopo Azzollini, Emmanuelle Barouk-Simonet, Julian Barwell, Muriel Belotti, Javier Benitez, Andreas Berger, Ake Borg, Angela R Bradbury, Joan Brunet, Saundra S Buys, Trinidad Caldes, Maria A Caligo, Ian Campbell, Sandrine M Caputo, Jocelyne Chiquette, Kathleen B M Claes, J Margriet Collée, Fergus J Couch, Isabelle Coupier, Mary B Daly, Rosemarie Davidson, Orland Diez, Susan M Domchek, Alan Donaldson, Cecilia M Dorfling, Ros Eeles, Lidia Feliubadaló, Lenka Foretova, Jeffrey Fowler, Eitan Friedman, Debra Frost, Patricia A Ganz, Judy Garber, Vanesa Garcia-Barberan, Gord Glendon, Andrew K Godwin, Encarna B Gómez Garcia, Jacek Gronwald, Eric Hahnen, Ute Hamann, Alex Henderson, Carolyn B Hendricks, John L Hopper, Peter J Hulick, Evgeny N Imyanitov, Claudine Isaacs, Louise Izatt, Ángel Izquierdo, Anna Jakubowska, Katarzyna Kaczmarek, Eunyoung Kang, Beth Y Karlan, Carolien M Kets, Sung-Won Kim, Zisun Kim, Ava Kwong, Yael Laitman, Christine Lasset, Min Hyuk Lee, Jong Won Lee, Jihyoun Lee, Jenny Lester, Fabienne Lesueur, Jennifer T Loud, Jan Lubinski, Noura Mebirouk, Hanne E J Meijers-Heijboer, Alfons Meindl, Austin Miller, Marco Montagna, Thea M Mooij, Patrick J Morrison, Emmanuelle Mouret-Fourme, Katherine L Nathanson, Susan L Neuhausen, Heli Nevanlinna, Dieter Niederacher, Finn C Nielsen, Robert L Nussbaum, Kenneth Offit, Edith Olah, Kai-Ren Ong, Laura Ottini, Sue K Park, Paolo Peterlongo, Georg Pfeiler, Catherine M Phelan, Bruce Poppe, Nisha Pradhan, Paolo Radice, Susan J Ramus, Johanna Rantala, Mark Robson, Gustavo C Rodriguez, Rita K Schmutzler, Christina G Hutten Selkirk, Payal D Shah, Jacques Simard, Christian F Singer, Johanna Sokolowska, Dominique Stoppa-Lyonnet, Christian Sutter, Yen Yen Tan, R Manuel Teixeira, Soo H Teo, Mary Beth Terry, Thomassen Mads, Tischkowitz Marc, E Toland Amanda, M Tucker Katherine, Tung Nadine, Christi J van Asperen, Klaartje van Engelen, Elizabeth J van Rensburg, Shan Wang-Gohrke, Barbara Wappenschmidt, Jeffrey N Weitzel, Drakoulis Yannoukakos, Mark H Greene, Matti A Rookus, Douglas F Easton, Georgia Chenevix-Trench, Antonis C Antoniou, David E Goldgar, Olufunmilayo I Olopade, Timothy R Rebbeck, Dezheng Huo
Background: BRCA1/2 mutations confer high lifetime risk of breast cancer, although other factors may modify this risk. Whether height or body mass index (BMI) modifies breast cancer risk in BRCA1/2 mutation carriers remains unclear. Methods: We used Mendelian randomization approaches to evaluate the association of height and BMI on breast cancer risk, using data from the Consortium of Investigators of Modifiers of BRCA1/2 with 14 676 BRCA1 and 7912 BRCA2 mutation carriers, including 11 451 cases of breast cancer...
October 12, 2018: Journal of the National Cancer Institute
https://www.readbyqxmd.com/read/30312118/a-randomized-controlled-trial-of-exercise-to-prevent-bone-loss-in-premenopausal-women-with-breast-cancer
#4
Laila S Tabatabai, Joan Bloom, Susan Stewart, Deborah E Sellmeyer
Background/Introduction/Objective: Premenopausal women treated for breast cancer are at high risk for bone loss. This trial examined the effects of a 1-year combined aerobic and resistance exercise program on bone mineral density (BMD) in women treated for premenopausal breast cancer. MATERIALS AND METHODS: Premenopausal women (n = 206) age ≤ 55 years at cancer diagnosis who were within two years of receiving adjuvant chemotherapy were randomized to a 12-month exercise program or a control group...
October 12, 2018: Journal of Women's Health
https://www.readbyqxmd.com/read/30308388/predictors-of-prolonged-benefit-from-palbociclib-plus-fulvestrant-in-women-with-endocrine-resistant-hormone-receptor-positive-human-epidermal-growth-factor-receptor-2-negative-metastatic-breast-cancer-in-paloma-3
#5
Massimo Cristofanilli, Angela DeMichele, Carla Giorgetti, Nicholas C Turner, Dennis J Slamon, Seock-Ah Im, Norikazu Masuda, Shailendra Verma, Sherene Loi, Marco Colleoni, Kathy Puyana Theall, Xin Huang, Yuan Liu, Cynthia Huang Bartlett
BACKGROUND: The addition of palbociclib to fulvestrant improved clinical outcomes over placebo-fulvestrant in endocrine-pretreated metastatic breast cancer (MBC) patients in PALOMA-3. Here, we examined factors predictive of long-term benefit. METHODS: Premenopausal-peri/postmenopausal patients with endocrine-resistant, hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative MBC were randomised 2:1 to fulvestrant (500 mg) and either palbociclib (125 mg/d; 3/1 schedule; n = 347) or placebo (n = 174)...
October 8, 2018: European Journal of Cancer
https://www.readbyqxmd.com/read/30300053/suboptimal-use-of-effective-contraceptive-methods-in-young-mexican-women-with-breast-cancer
#6
Andrea Castro-Sanchez, Bertha Alejandra Martinez-Cannon, Alejandra Platas, Alejandro Mohar, Alan Fonseca, Yoatzin Vega, Adrian Fimbres-Morales, Cynthia Villarreal-Garza
PURPOSE: Contraceptive counseling and adherence in young women with breast cancer (BC) is a relevant issue because chemotherapy and hormonal treatment resulting in amenorrhea do not preclude unintended pregnancies. Currently, there is limited evidence from high-income countries; however, there are no studies regarding use of contraceptives in patients with BC in Mexico. This study aimed to determine the rate of contraceptive use in young Mexican women with BC during cancer treatment, characterize their contraceptive preferences, and assess contraceptive counseling by Mexican physicians...
October 2018: Journal of Global Oncology
https://www.readbyqxmd.com/read/30299292/risk-stratification-in-early-breast-cancer-in-premenopausal-and-postmenopausal-women-integrating-genomic-assays-with-clinicopathological-features
#7
Ivana Sestak
PURPOSE OF REVIEW: There is growing consensus that genomic assays provide useful complementary information to clinicopathological features in oestrogen receptor (ER)-positive breast cancers. Here, ongoing research with multigene tests used for postmenopausal breast cancer and new emerging prognostic and predictive markers for pre- and postmenopausal women are summarised. RECENT FINDINGS: Results of the TAILORx trial have shown that women with an intermediate risk score do not benefit from adjuvant chemotherapy...
October 5, 2018: Current Opinion in Oncology
https://www.readbyqxmd.com/read/30299291/impact-of-ovarian-function-suppression-in-premenopausal-women-with-estrogen-receptor-positive-early-breast-cancer
#8
Matteo Lambertini, Giulia Viglietti, Evandro de Azambuja
PURPOSE OF THE REVIEW: This manuscript aims at providing an updated overview on the role of adding ovarian function suppression to tamoxifen or an aromatase inhibitor as adjuvant endocrine therapy in premenopausal women with estrogen receptor (ER)-positive early breast cancer. RECENT FINDINGS: Until recently, tamoxifen alone was the only standard adjuvant treatment option for premenopausal women with ER-positive disease. However, recent important evidence has contributed to significantly modify the endocrine treatment landscape in this setting...
October 5, 2018: Current Opinion in Oncology
https://www.readbyqxmd.com/read/30291812/changes-in-cardiovascular-disease-risk-and-risk-factors-among-women-with-and-without-breast-cancer
#9
Chelsea Anderson, Hazel B Nichols, Allison M Deal, Yong-Moon Mark Park, Dale P Sandler
BACKGROUND: Cardiovascular disease (CVD) risk is an important health concern among survivors of breast cancer. However, few studies to date have examined whether trajectories of CVD risk and major risk factors are worse among women with a breast cancer diagnosis compared with those without. METHODS: Changes in weight, body mass index, waist circumference, systolic blood pressure, and 10-year CVD risk were compared between women with (813 women) and without (1049 women) an incident breast cancer diagnosis while they were enrolled in the National Institute of Environmental Health Sciences Sister Study cohort...
October 6, 2018: Cancer
https://www.readbyqxmd.com/read/30284064/sugar-sweetened-beverage-consumption-and-incidence-of-breast-cancer-the-seguimiento-universidad-de-navarra-sun-project
#10
A Romanos-Nanclares, Estefania Toledo, I Gardeazabal, J J Jiménez-Moleón, M A Martínez-González, A Gea
PURPOSE: Breast cancer (BC) incidence is increasing worldwide. Higher insulin resistance may potentially lead to an increased risk of BC. Sugar-sweetened beverages (SSB) are an acknowledged dietary factor that increases insulin resistance. However, the association between SSB and BC has not been widely explored. We evaluated the association between baseline consumption of SSB and the incidence of BC among relatively young women in a cohort of Spanish university graduates. METHODS: We evaluated 10,713 middle-aged, Spanish female university graduates (median age 33) from the Seguimiento Universidad de Navarra (SUN) cohort, initially free of BC...
October 3, 2018: European Journal of Nutrition
https://www.readbyqxmd.com/read/30282414/impact-of-hormonal-therapy-and-other-adjuvant-therapies-on-contralateral-breast-volume-change-after-implant-based-breast-reconstruction
#11
Jung Youl Park, Jae-Ho Chung, Hyung Chul Lee, Byung-Il Lee, Seung-Ha Park, Eul-Sik Yoon
BACKGROUND: Adjuvant therapy after breast surgery, including tamoxifen or aromatase inhibitors, improves the postoperative outcomes and long-term survival of breast cancer patients. The aim of this study was to determine whether volume changes occurred in the contralateral breast during hormonal or other adjuvant therapies. METHODS: This study reviewed 90 patients who underwent unilateral breast reconstruction between September 2012 and April 2018 using tissue expanders and a permanent implant after the surgical removal of breast cancer...
September 2018: Archives of Plastic Surgery
https://www.readbyqxmd.com/read/30273052/healthy-eating-index-2010-and-breast-cancer-risk
#12
Fatemeh Sedaghat, Zeinab Heidari, Saba Jalali, Azam Doustmohammadian, Mehdi Ehteshami, Bahram Rashidkhani
BACKGROUND: The role of dietary quality indexes for predicting breast cancer (BrCa) risk remains inconclusive. We aimed to assess the relation between healthy eating index 2010 (HEI-2010) and BrCa risk in a case-control study in Iranian women. METHOD: The 272 hospitalized controls and 136 newly diagnosed BrCa cases were recruited from two major hospitals. Food frequency questionnaire (FFQ) data were then utilized to calculate the HEI-2010 scores. Logistic regression models were used to calculate odds ratios (OR) and 95% confidence intervals (CIs) between tertiles of HEI-2010 and BrCa risk, adjusting for potential confounders...
October 1, 2018: Nutrition and Cancer
https://www.readbyqxmd.com/read/30261866/an-italian-delphi-study-to-evaluate-consensus-on-adjuvant-endocrine-therapy-in-premenopausal-patients-with-breast-cancer-the-era-project
#13
Giacomo Pelizzari, Grazia Arpino, Laura Biganzoli, Saverio Cinieri, Michelino De Laurentiis, Lucia Del Mastro, Angelo Di Leo, Stefania Gori, Valentina Guarneri, Paolo Marchetti, Fabio Puglisi
BACKGROUND: Several trials evaluated the role of ovarian function suppression for the adjuvant treatment of premenopausal patients with hormone receptor-positive early breast cancer. Based on the results of the SOFT and TEXT trials, international guidelines recommend the addition of ovarian function suppression to standard adjuvant endocrine therapy for patients at higher risk of relapse. METHODS: The ERA project (Evaluation of Risk factors in the Adjuvant treatment of breast cancer in premenopausal patients) was devised with the objective of obtaining a consensus on the identification of risk factors and the use of ovarian function suppression in the adjuvant treatment of these women...
September 27, 2018: BMC Cancer
https://www.readbyqxmd.com/read/30247577/diet-quality-scores-inversely-associated-with-postmenopausal-breast-cancer-risk-are-not-associated-with-premenopausal-breast-cancer-risk-in-the-california-teachers-study
#14
Vikram Haridass, Argyrios Ziogas, Susan L Neuhausen, Hoda Anton-Culver, Andrew O Odegaard
Background: Evidence for the association between diet and breast cancer risk is inconsistent Thus, research that compares indexes of overall diet quality may provide new insight. Objective: We examined the association between diet quality indexes and pre- and postmenopausal breast cancer risk in a large prospective cohort. Methods: This was a prospective analysis of 96,959 women, aged 22-104 y, in the California Teachers Study cohort (1995-2011)...
September 22, 2018: Journal of Nutrition
https://www.readbyqxmd.com/read/30241966/individualized-prediction-of-menses-recovery-after-chemotherapy-for-early-stage-breast-cancer-a-nomogram-developed-from-unicancer-pacs04-and-pacs05-trials
#15
Barbara Pistilli, Chafika Mazouni, Anna Zingarello, Matthieu Faron, Mahasti Saghatchian, Michael Grynberg, Marc Spielmann, Paul Kerbrat, Henri Roché, Veronique Lorgis, Thomas Bachelot, Mario Campone, Christelle Levy, Anthony Gonçalves, Anne Lesur, Corinne Veyret, Laurence Vanlemmens, Jerome Lemonnier, Suzette Delaloge
BACKGROUND: The likelihood of menses recovery varies greatly in premenopausal patients receiving adjuvant chemotherapy for breast cancer. Quantifying this probability for each patient could better inform the chemotherapy discussion and individualize fertility counseling. We performed a pooled analysis of the PACS04 and PACS05 adjuvant randomized trials to develop a nomogram to estimate the probability of menses recovery at 3, 6, and 18 months after the end of adjuvant chemotherapy. PATIENTS AND METHODS: Women who were premenopausal and aged ≤ 50 years at randomization in the PACS04 and PACS05 trials were included in the present analysis...
August 23, 2018: Clinical Breast Cancer
https://www.readbyqxmd.com/read/30236925/breast-cancer-metastasis-molecular-subtypes-and-overweight-and-obesity-in-veracruz-mexico
#16
Carlos Adrián Alarcón Rojas, María Teresa Alvarez-Bañuelos, Jaime Morales-Romero, Héctor Suárez-Díaz, Juan Carlos Hernández-Fonseca, Guillermo Contreras-Alarcón
INTRODUCTION: We assessed the association between overweight, obesity, and morbid obesity with the incidence of the most aggressive breast cancer subtypes in women. METHODS AND MATERIALS: A cross-sectional study was performed. We conducted a record review to identify the following aspects: body mass index, sociodemographic features, tumor characteristics, and reproductive and molecular aspects. Descriptive statistics and univariate analysis were performed to identify the association between the molecular subtypes and the study variables...
August 22, 2018: Clinical Breast Cancer
https://www.readbyqxmd.com/read/30235017/dietary-inflammatory-index-and-odds-of-breast-cancer-in-a-case-control-study-from-iran
#17
Saba Jalali, Nitin Shivappa, James R Hébert, Zeinab Heidari, Azita Hekmatdoost, Bahram Rashidkhani
Chronic inflammation is implicated in breast cancer (BrCa) development; however, studies on the association of the inflammatory potential of diet and breast cancer have produced conflicting results. With this as background, we investigated the association between dietary inflammatory index (DII® ) scores and BrCa risk in an Iranian case-control study. In this study, 136 newly diagnosed breast cancer patients and 272 hospitalized controls were recruited using convenience sampling. DII scores were computed from dietary intake data collected through a validated food frequency questionnaire (FFQ)...
September 20, 2018: Nutrition and Cancer
https://www.readbyqxmd.com/read/30223226/fulvestrant-plus-goserelin-versus-anastrozole-plus-goserelin-versus-goserelin-alone-for-hormone-receptor-positive-her2-negative-tamoxifen-pretreated-premenopausal-women-with-recurrent-or-metastatic-breast-cancer-kcsg-br10-04-a-multicentre-open-label-three-arm
#18
Ji-Yeon Kim, Seock-Ah Im, Kyung Hae Jung, Jungsil Ro, Joohyuk Sohn, Jee Hyun Kim, Yeon Hee Park, Tae-Yong Kim, Sung-Bae Kim, Keun Seok Lee, Gun Min Kim, Se Hyun Kim, Seonwoo Kim, Jin Seok Ahn, Kyung-Hun Lee, Jin-Hee Ahn, In Hae Park, Young-Hyuck Im
BACKGROUND: We investigated the efficacy and safety of fulvestrant plus goserelin (F + G) versus anastrozole plus goserelin (A + G) in comparison with goserelin (G) alone in premenopausal women with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-), tamoxifen-pretreated metastatic breast cancer (MBC). PATIENTS AND METHODS: In this multicentre, open-label, randomised phase II study, premenopausal women aged ≥18 years with HR+, HER2-, tamoxifen-pretreated MBC were randomly assigned (1:1:1) to F + G, A + G or G alone...
September 14, 2018: European Journal of Cancer
https://www.readbyqxmd.com/read/30210227/evaluation-of-menopausal-status-among-breast-cancer-patients-with-chemotherapy-induced-amenorrhea
#19
Bailin Zhang, Jinqi Wu, Rongshou Zheng, Qian Zhang, Margaret Zhuoer Wang, Jun Qi, Haijing Liu, Yipeng Wang, Yang Guo, Feng Chen, Jing Wang, Wenyue Lyu, Jidong Gao, Yi Fang, Wanqing Chen, Xiang Wang
Objective: In patients with chemotherapy-induced amenorrhea (CIA), the menopausal status is ambiguous and difficult to evaluate. This study aimed to establish a discriminative model to predict and classify the menopausal status of breast cancer patients with CIA. Methods: This is a single center hospital-based study from 2013 to 2016. The menopausal age distribution and accumulated incidence rate of CIA are described. Multivariate models were adjusted for established and potential confounding factors including age, serum concentration of estradiol (E2) and follicle-stimulating hormone (FSH), feeding, pregnancy, parity, abortions, and body mass index (BMI)...
August 2018: Chinese Journal of Cancer Research, Chung-kuo Yen Cheng Yen Chiu
https://www.readbyqxmd.com/read/30181556/the-prognostic-effects-of-somatic-mutations-in-er-positive-breast-cancer
#20
Obi L Griffith, Nicholas C Spies, Meenakshi Anurag, Malachi Griffith, Jingqin Luo, Dongsheng Tu, Belinda Yeo, Jason Kunisaki, Christopher A Miller, Kilannin Krysiak, Jasreet Hundal, Benjamin J Ainscough, Zachary L Skidmore, Katie Campbell, Runjun Kumar, Catrina Fronick, Lisa Cook, Jacqueline E Snider, Sherri Davies, Shyam M Kavuri, Eric C Chang, Vincent Magrini, David E Larson, Robert S Fulton, Shuzhen Liu, Samuel Leung, David Voduc, Ron Bose, Mitch Dowsett, Richard K Wilson, Torsten O Nielsen, Elaine R Mardis, Matthew J Ellis
Here we report targeted sequencing of 83 genes using DNA from primary breast cancer samples from 625 postmenopausal (UBC-TAM series) and 328 premenopausal (MA12 trial) hormone receptor-positive (HR+) patients to determine interactions between somatic mutation and prognosis. Independent validation of prognostic interactions was achieved using data from the METABRIC study. Previously established associations between MAP3K1 and PIK3CA mutations with luminal A status/favorable prognosis and TP53 mutations with Luminal B/non-luminal tumors/poor prognosis were observed, validating the methodological approach...
September 4, 2018: Nature Communications
keyword
keyword
165278
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"